Eton Pharmaceuticals (ETON) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 9, 2026, with voting available online, by phone, mail, or live at the meeting for shareholders of record as of April 10, 2026.

• Key proposals include electing two Class II directors and ratifying the appointment of Grant Thornton LLP as the independent auditor for 2026.

• Proxy materials are available online, and shareholders are encouraged to vote promptly to ensure quorum.

• Forward-looking statements are subject to risks detailed in the company’s SEC filings.

Voting matters and shareholder proposals

• Shareholders will vote on electing Jenn Adams and Charles J. Casamento as Class II directors for terms expiring in 2029.

• Ratification of Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026 is on the agenda.

• Procedures for submitting shareholder proposals for future meetings are outlined, with specific deadlines for the 2027 meeting.

Board of directors and corporate governance

• The board consists of five members divided into three staggered classes, with a majority being independent directors.

• Board committees include audit, compensation, and nominating/governance, each composed entirely of independent directors.

• The chairman and CEO roles are separated to enhance governance and oversight.

• Directors bring diverse experience in pharmaceuticals, finance, and governance, and board diversity is emphasized.

• Directors are expected to attend and actively participate in meetings; all attended at least 90% of meetings in 2025.